ASX Announcements
Market Sensitive
Appendix 4D and Half Year Financial Report
Half Yearly Report, Half Year Audit Review, Half Year Directors' Statement, Half Year Accounts, Half Year Directors' Report
Market Sensitive
Activities Report and Appendix 4C
CTE – Second Quarter Cashflow Report, CTE - Second Quarter Activity Report
Section 708A Cleansing Statement
Cleansing Notice
November 2021
Listed biotech Invion raising $15m
Life sciences outfit Invion is seeking $15 million to expand its technology licences for cancer treatment.
February 2016
Law firm Jones Day keen to cash in on resources bust
International law firms used to be attracted to Australia because of the burgeoning commodities market but now they are expanding because of the resources slump.
January 2015
Can Invion cough up the secret to quitting smoking?
Invion may have uncovered a breakthrough for smokers trying to quit, after interim clinical trial data showed the drug nadalol reduced markers of lung inflammation associated with smoker’s cough.
Low Aussie dollar could spur biotech takeovers
A string of high-profile setbacks may have whittled away support for biotechnology companies, but executives and analysts say there is still plenty of money from overseas and the weak Australian dollar may spur a series of takeovers by foreign buyers.